Vanadis Core® qualitative assay for screening the risk of trisomy 21, 18, and/or 13.
Products may not be licenced in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.
Qualitative assay intended for an in vitro diagnostic use to act as an aid in screening for the risk of trisomy 21, 18, and/or 13 in fetus using cell-free DNA from pregnant women of at least 10 weeks of gestation.
Application |
Noninvasive Prenatal Testing (NIPT)
|
---|---|
Brand |
Vanadis Core®
|
Product Compatibility |
Vanadis Core®
|
We are here to answer your questions.